Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals
January 08, 2021 19:39 ET
|
Ascendis Pharma
– Advances Vision 3x3 to extend global clinical and commercial reach – COPENHAGEN, Denmark, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company...
Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021 07:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product...
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
December 30, 2020 16:05 ET
|
Ascendis Pharma
- TransCon TLR7/8 Agonist is designed for intratumoral, sustained release of resiquimod with minimal systemic exposure, while inducing a potent anti-tumor response - COPENHAGEN, Denmark, Dec. ...
Ascendis Pharma A/S Announces Planned Board Transition
December 14, 2020 16:05 ET
|
Ascendis Pharma
– Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting – – Board of Directors intends to appoint Dr. Albert Cha to serve as Chair after 2021...
Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
November 25, 2020 07:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product...
Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20
November 11, 2020 17:30 ET
|
Ascendis Pharma
– Event will provide an overview of how Ascendis is applying its TransCon™ technology platform and its unique algorithm for product innovation to the therapeutic area of oncology – COPENHAGEN,...
Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results
November 11, 2020 16:01 ET
|
Ascendis Pharma
– European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) for TransConTM hGH (lonapegsomatropin) in pediatric growth hormone deficiency (GHD) – – Submitted...
Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases
November 03, 2020 07:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 11
November 02, 2020 16:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe
October 23, 2020 08:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...